2202 Kidney transplant recipients with 10 years of graft function: What happens next?

American Journal of Transplantation

Volumn 8, Issue 11, 2008, Pages 2410-2419

  Matas, A J ^a   Gillingham, K J ^a   Humar, A ^a   Kandaswamy, R ^a   Sutherland, D E R ^a   Payne, W D ^a   Dunn, T B ^a   Najarian, J S ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Graft loss; Kidney; Outcomes

Indexed keywords

ADULT; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FIBROSING ALVEOLITIS; GRAFT SURVIVAL; HUMAN; KIDNEY DISEASE; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LIVING DONOR; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RECIPIENT; SKIN CANCER; SURVIVAL;

EID: 53749104371     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2008.02414.x     Document Type: Article

References (37)

1. Wolfe RA, Ashby VB, Mitford EL et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999 341 : 1725 1730.
2. Evans RW, Manninen DL, Garrison LP Jr. et al. The quality of life of patients with end-stage renal disease. N Engl J Med 1985 312 : 553 559.
3. Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003 75 : 1291 1295.
4. Matas AJ, Sutherland DE, Najarian JS. Evolution of immunosuppression at the University of Minnesota. Transplant Proc 2004 36 (Suppl 2 64S 70S.
5. Dunn DL, Gillingham KJ, Kramer MA et al. A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation. Transplantation 1994 57 : 876 884.
6. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999 55 : 713 723.
7. Cecka JM. The UNOS scientific renal transplant registry - 2000. In : Cecka JM, Terasaki PI (eds). Clinical Transplants. Los Angeles, CA : UCLA Tissue Typing Laboratory, 2000 1 18.
8. Arend SM, Mattat MJK, Westendorp RJW, Van Der Woude FJ, van Es LA. Patient survival after renal transplantation; more than 25 years follow-up. Nephrol Dial Transplant 1997 12 : 1672 1679.
9. Tangeraas T, Bjerre A, Lien B et al. Long-term outcome of pediatric renal transplantation: The Norwegian experience in three eras, 1970-2006. Pediatr Transplant 2008 Jan 14 (Epub ahead of print).
10. Gheith OA, Bakr MA, Fouda MA, Shokeir AA, Sobh M, Ghoneim M. Prospective randomized study of azathioprine versus cyclosporine based therapy in primary haplo-identical living-donor kidney transplantation: 20-year experience. Clin Exp Nephrol 2007 11 : 151 155.
11. Webster AC, Craig JC, Simpson JM, Jones MP, Chapman JR. Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: A cohort study of 15,183 recipients. Am J Transplant 2007 7 : 2140 2151.
12. Bordea C, Wojnarowska F, Millard PR, Doll H, Welsh K, Morris PJ. Skin cancers in renal-transplant recipients occur more frequently than previously recognized in a temperate climate. Transplantation 2004 77 : 574 579.
13. Faull RJ, Hollett P, McDonald SP. Lymphoproliferative disease after renal transplantation in Australia and New Zealand. Transplantation 2005 80 : 193 197.
14. Bordea C, Wojnarowska F, Millard PR, Doll H, Welsh K, Morris PJ. Skin cancers in renal-transplant recipients occur more frequently than previously recognized in a temperate climate. Transplantation 2004 77 : 574 579.
15. London NJ, Farmery SM, Will EJ, Davison AM, Lodge JP. Risk of neoplasia in renal transplant patients. Lancet 1995 346 : 403 406.
16. Vanrenterghem YFC, Claes K, Montagnino G et al. Risk factors for cardiovascular events after successful renal transplantation. Transplantation 2008 85 : 209 216.
17. Cosio FG, Alamir A, Yim S et al. Patient survival after renal transplantation: I. The impact of dialysis pre-transplant. Kidney Int 1998 53 : 767 772.
18. Mange KC, Joffe MM, Feldman HI. Effect of the use or nonuse of long-term dialysis on the subsequent survival of renal transplants from living donors. N Engl J Med 2001 344 : 726 731.
19. Meier-Kriesche HU, Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes - A paired donor kidney analysis. Transplantation 2002 74 : 1377 1381.
20. Matas AJ, Humar A, Gillingham KJ et al. Five preventable causes of kidney graft loss in the 1990s: A single-center analysis. Kidney Int 2002 62 : 704 714.
21. Meier-Kriesche HU, Schold JD, Srinivas TR, Reed A, Kaplan A. Kidney transplantation halts cardiovascular disease progression in patients with end-stage renal disease. Am J Transplant 2004 4 : 1662 1668.
22. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003 42 : 1050 1065.
23. Fried LF, Shlipak MG, Crump C et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol 2003 41 : 1364 1372.
24. Anavekar NS, McMurray JJV, Velazquez EJ et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004 351 : 1285 1295.
25. Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002 62 : 311 318.
26. Woo YM, Jardine AG, Clark AF et al. Early graft function and patient survival following cadaveric renal transplantation. Kidney Int 1999 55 : 692 699.
27. Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003 75 : 1291 1295.
28. Fellström B, Jardine AG, Soveri I et al., Assessment of Lescol in Renal Transplantation trial. Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: Experience from the Assessment of Lescol in Renal Transplantation trial. Transplantation 2005 79 : 1160 1163.
29. Holdaas H, Fellström B, Jardine AG et al., Assessment of Lescol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. Lancet 2003 361 : 2024 2031.
30. Jardine AG, Holdaas H, Fellström B, Cole E, Nyberg G, Grönhagen-Riska C, ALERT Study Investigators. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: Post-hoc subgroup analyses of the ALERT Study. Am J Transplant 2004 4 : 988 995.
31. Excerpts from the United States Renal Data System. 2007 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States. AJKD 2008 51 (1 suppl 1 S169.
32. Matas AJ, Kandaswamy R, Gillingham KJ et al. Prednisone-free maintenance immunosuppression - a 5-year experience. Am J Transplant 2005 5 : 2473 2478.
33. Matas AJ. Minimization of steroids in kidney transplantation. Transpl Int 2008 (Epub ahead of print).
34. Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: Focus on improving renal function and nephrotoxicity. Clin Transplant 2008 22 : 1 15.
35. Grinyó JM, Cruzado JM. Mycophenolate mofetil and sirolimus combination in renal transplantation. Am J Transplant 2006 6 : 1991 1999.
36. Gallagher MP, Hall B, Craig J, Berry G, Tiller DJ, Eris J, Australian Multicenter Trial of Cyclosporine Withdrawal Study Group and the ANZ Dialysis and Transplantation Registry. A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-year results. Transplantation 2004 78 : 1653 1660.
37. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004 4 : 1289 1295.